Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


California HIV bill

This article was originally published in The Gray Sheet

Executive Summary

Gov. Arnold Schwarzenegger (R) signs into law Assembly Bill 1984, which requires health care service plans and insurers to provide HIV testing regardless of its relation to a primary diagnosis, on Oct. 1. Introduced by Assembly Member Paul Krekorian, D-Burbank, the law is a "first-in-the-nation piece of legislation," according to the AIDS Healthcare Foundation. The measure is intended to help the state comply with revised HIV testing guidelines issued by the Centers for Disease Control in 2006. AB 1984 had been held up as California legislators grappled with passing a fiscal 2009 budget (1"The Gray Sheet" Sept. 8, 2008, p. 19)

You may also be interested in...

Calif. Bill Requiring HIV Test Coverage May Be Delayed By Budget Stalemate

Whether California state legislation requiring insurers to cover routine HIV/AIDS tests is signed by Gov. Arnold Schwarzenegger appears to depend largely on whether lawmakers can agree on a budget for fiscal 2009

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts